AZN shaking up senior management team

AstraZeneca plc (LSE:AZN; NYSE:AZN) said that Martin Mackay, president of R&D, and Tony Zook, EVP of global commercial, will depart at the end of January. Effective immediately, the pharma created three senior R&D positions responsible for discovery and early stage development of small molecules, discovery and early stage development of biologics and late stage development. AstraZeneca also created three new positions responsible for the commercial regions of North America, Europe and international. Additionally, the pharma created a position that is responsible for its global portfolio and product strategy to serve as a bridge between R&D and AstraZeneca's sales organization. The pharma could not be reached for details. ...